We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
TODAY'S HIGH
605.5
TODAY'S LOW
589
52 WEEK HIGH
695.95
52 WEEK LOW
436.8
% of Shares Held by
All Insider
37.58%
% of Shares Held by
Institutions
23.00%
% of Float Held by
Institutions
36.84%
Number of Institutions
Holding Shares
75
MARKET CAP
31733.73 Cr.
ETERPRISE VALUE
32131.18 Cr.
NO. OF SHARES
53.73 Cr.
BOOK VALUE
62.364
DIV. YIELD
1.2%
DEBT
1776.66 Cr.
GROSS PROFIT
2686.75 Cr.
CASH
75.94 Cr.
REVENUE
5196 Cr.
REVENUE/SHARE
96.771
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | -27.60 Cr. | -27.60 Cr. | -27.60 Cr. | -27.60 Cr. |
| Change To Liabilities | -301.21 Cr. | 559.52 Cr. | 112.26 Cr. | 186.17 Cr. |
| Total cashflows from Investing Activities | -914.34 Cr. | -940.99 Cr. | -221.13 Cr. | -252.87 Cr. |
| Net Borrowings | 196.81 Cr. | 380.40 Cr. | -5.82 Cr. | 56.41 Cr. |
| Total Cash from Financing Activities | 30.26 Cr. | 254.70 Cr. | -127.66 Cr. | -44.77 Cr. |
| Other Liabilities | 185.51 Cr. | 30.33 Cr. | -23.45 Cr. | 15.56 Cr. |
| Total Assets | 4.31 Cr. | 7.38 Cr. | 2.61 Cr. | 2.43 Cr. |
| Net Income | 827.52 Cr. | 983.58 Cr. | 255.27 Cr. | 93.76 Cr. |
| Change in Cash | 26.89 Cr. | 46.77 Cr. | -1.28 Cr. | -3.60 Lakhs |
| Effect of Exchange Rate | -13 Lakhs | 6 Lakhs | 9 Lakhs | -5.30 Lakhs |
| Total Cash from Operating Activities | 911.10 Cr. | 733 Cr. | 347.42 Cr. | 297.66 Cr. |
| Depreciation | 251.49 Cr. | 201.38 Cr. | 183.46 Cr. | 160.49 Cr. |
| Other Cashflows from Investing Activities | -10.02 Cr. | 1.17 Cr. | 90 Lakhs | 88.40 Lakhs |
| Dividends Paid | -85.86 Cr. | -75.04 Cr. | -32 Cr. | -15.90 Cr. |
| Change to Inventory | -174.33 Cr. | -660.17 Cr. | -223.23 Cr. | -96.90 Cr. |
| Change to Account Receivables | -51.58 Cr. | -523.74 Cr. | -65.34 Cr. | -149.28 Cr. |
| Other Cashflows from Financing Activities | -85 Cr. | -58.04 Cr. | -92.45 Cr. | -87.71 Cr. |
| Change to Net Income | 173.70 Cr. | 138.41 Cr. | 104.64 Cr. | 84.16 Cr. |
| Capital Expenditures | -876.84 Cr. | -688.77 Cr. | -222.19 Cr. | -254.26 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 1083.65 Cr. | 1301.11 Cr. | 293.61 Cr. | 119.75 Cr. |
| Minority Interest | 7.86 Cr. | 3.15 Cr. | 3.15 Cr. | 3.15 Cr. |
| Net Income | 1170.94 Cr. | 1350.65 Cr. | 383.15 Cr. | 214.93 Cr. |
| Selling General Administrative | 501.53 Cr. | 438.01 Cr. | 355.41 Cr. | 303.68 Cr. |
| Gross Profit | 2741.80 Cr. | 2614.48 Cr. | 1385.61 Cr. | 1027.46 Cr. |
| Ebit | 1170.94 Cr. | 1350.65 Cr. | 383.15 Cr. | 214.93 Cr. |
| Operating Income | 1170.94 Cr. | 1350.65 Cr. | 383.15 Cr. | 214.93 Cr. |
| Other Operating Expenses | 817.84 Cr. | 620.75 Cr. | 459.78 Cr. | 344.65 Cr. |
| Interest Expense | -102.39 Cr. | -56.12 Cr. | -73.39 Cr. | -74.23 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 251.42 Cr. | 317.29 Cr. | 38.34 Cr. | 25.98 Cr. |
| Total Revenue | 4935.57 Cr. | 4813.51 Cr. | 2831.72 Cr. | 2291.91 Cr. |
| Total Operating Expenses | 3764.63 Cr. | 3462.86 Cr. | 2448.57 Cr. | 2076.98 Cr. |
| Cost of Revenue | 2193.77 Cr. | 2199.03 Cr. | 1446.11 Cr. | 1264.45 Cr. |
| Total Other Income Expense Net | -87.29 Cr. | -49.54 Cr. | -89.54 Cr. | -95.18 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 832.23 Cr. | 983.82 Cr. | 255.27 Cr. | 93.76 Cr. |
| Net Income Applicable to Common Shares | 827.52 Cr. | 983.58 Cr. | 255.27 Cr. | 93.76 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 10.83 Cr. | 9.32 Cr. | 9.75 Cr. | 12.13 Cr. |
| Capital Surplus | 0 | 694.77 Cr. | 685.20 Cr. | 678.66 Cr. |
| Total Liabilities | 3608.99 Cr. | 3149.99 Cr. | 1980.55 Cr. | 1772.77 Cr. |
| Stock Holder Equity | 3351.19 Cr. | 2597.55 Cr. | 1769.77 Cr. | 1558.40 Cr. |
| Minority Interest | 7.86 Cr. | 3.15 Cr. | 0 | 0 |
| Other Liabilities | 647.46 Cr. | 225.12 Cr. | 162.60 Cr. | 142.07 Cr. |
| Total Assets | 6968.04 Cr. | 5750.69 Cr. | 3750.32 Cr. | 3331.18 Cr. |
| Common Stock | 107.47 Cr. | 107.32 Cr. | 106.91 Cr. | 106.43 Cr. |
| Retained Earnings | 0 | 1883.29 Cr. | 987.59 Cr. | 771.12 Cr. |
| Other Liabilities | 292.01 Cr. | 237.41 Cr. | 102.59 Cr. | 90.16 Cr. |
| Good Will | 246.30 Cr. | 246.30 Cr. | 9.74 Cr. | 9.73 Cr. |
| Treasury Stock | 3243.72 Cr. | -87.83 Cr. | -9.93 Cr. | 2.18 Cr. |
| Other Assets | 126.93 Cr. | 139.63 Cr. | 141.33 Cr. | 126.12 Cr. |
| Cash | 75.94 Cr. | 48.46 Cr. | 1.74 Cr. | 3.02 Cr. |
| Current Liabilities | 2681.01 Cr. | 2457.15 Cr. | 1692.38 Cr. | 1423.90 Cr. |
| Long Term Asset Charges | 0 | 0 | 73.93 Cr. | 53.38 Cr. |
| Short Long Term Debt | 1135.69 Cr. | 137.92 Cr. | 101.34 Cr. | 93.01 Cr. |
| Other Stockholder Equity | 3243.72 Cr. | -87.83 Cr. | -9.93 Cr. | 2.18 Cr. |
| Property Plant Equipment | 3208.56 Cr. | 2277.17 Cr. | 1774.03 Cr. | 1716.83 Cr. |
| Total Cur. Assets | 3344.61 Cr. | 3074.86 Cr. | 1812.06 Cr. | 1462.95 Cr. |
| Long Term Investments | 30.81 Cr. | 3.41 Cr. | 3.41 Cr. | 3.40 Cr. |
| Net Tangible Assets | 3094.06 Cr. | 2341.93 Cr. | 1750.28 Cr. | 1536.53 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 1354.82 Cr. | 1345.71 Cr. | 831.17 Cr. | 731.33 Cr. |
| Long Term Debt | 596.34 Cr. | 429.16 Cr. | 165.02 Cr. | 258.71 Cr. |
| Inventory | 1760.30 Cr. | 1575.45 Cr. | 905.22 Cr. | 681.93 Cr. |
| Accounts Payable | 876.37 Cr. | 1178.69 Cr. | 615.63 Cr. | 488.31 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account